{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T17:55:13Z","timestamp":1781373313178,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00415-026-13923-w","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:15:05Z","timestamp":1780571705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tocilizumab for severe immune checkpoint inhibitor myopathy\u2013myocarditis: acute and long-term outcomes"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0700-4541","authenticated-orcid":false,"given":"Gurpreet","family":"Chaggar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0045-7278","authenticated-orcid":false,"given":"Bridget","family":"Mulvany-Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4411-0581","authenticated-orcid":false,"given":"Matthew","family":"Anaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8500-2360","authenticated-orcid":false,"given":"Brendan","family":"Putko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3512-1796","authenticated-orcid":false,"given":"Grayson","family":"Beecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"6382","key":"13923_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"issue":"11","key":"13923_CR2","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000210031","volume":"103","author":"G Beecher","year":"2024","unstructured":"Beecher G, Pinal-Fernandez I, Mammen AL, Liewluck T (2024) Immune checkpoint inhibitor myopathy: the double-edged sword of cancer immunotherapy. Neurology 103(11):e210031. https:\/\/doi.org\/10.1212\/wnl.0000000000210031","journal-title":"Neurology"},{"issue":"2","key":"13923_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa181","volume":"2","author":"S Shelly","year":"2020","unstructured":"Shelly S, Triplett JD, Pinto MV et al (2020) Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun 2(2):fcaa181. https:\/\/doi.org\/10.1093\/braincomms\/fcaa181","journal-title":"Brain Commun"},{"issue":"36","key":"13923_CR4","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/jco.21.01440","journal-title":"J Clin Oncol"},{"key":"13923_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA et al (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002435","journal-title":"J Immunother Cancer"},{"key":"13923_CR6","unstructured":"National Cancer Institute. Common terminology criteria for adverse events version 5.0. NIH Publication. 2017. URL: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."},{"issue":"16_suppl","key":"13923_CR7","doi-asserted-by":"publisher","first-page":"9538","DOI":"10.1200\/JCO.2024.42.16_suppl.9538","volume":"42","author":"JS Weber","year":"2024","unstructured":"Weber JS, Puranik A, Mitzutani T et al (2024) Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma. J Clin Oncol 42(16_suppl):9538\u20139538. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9538","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"13923_CR8","doi-asserted-by":"publisher","first-page":"9553","DOI":"10.1200\/JCO.2024.42.16_suppl.9553","volume":"42","author":"B Anouti","year":"2024","unstructured":"Anouti B, McVay K, Abraham M et al (2024) Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: clinical outcomes and biomarker analysis. J Clin Oncol 42(16_suppl):9553\u20139553. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9553","journal-title":"J Clin Oncol"},{"key":"13923_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006814","author":"F Fa'ak","year":"2023","unstructured":"Fa\u2019ak F, Buni M, Falohun A et al (2023) Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2023-006814","journal-title":"J Immunother Cancer"},{"issue":"3","key":"13923_CR10","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/1078155217745144","volume":"25","author":"CR Stroud","year":"2019","unstructured":"Stroud CR, Hegde A, Cherry C et al (2019) Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract 25(3):551\u2013557. https:\/\/doi.org\/10.1177\/1078155217745144","journal-title":"J Oncol Pharm Pract"},{"key":"13923_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005111","author":"RB Holmstroem","year":"2022","unstructured":"Holmstroem RB, Nielsen OH, Jacobsen S et al (2022) COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-005111","journal-title":"J Immunother Cancer"},{"issue":"4","key":"13923_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.21037\/cdt-24-114","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang Y, Li S, Shi H, Guan X, Wei Q, Chen D (2024) Therapeutic agents for steroid-refractory immune checkpoint inhibitor-related myocarditis: a narrative review. Cardiovasc Diagn Ther 14(4):679\u2013697. https:\/\/doi.org\/10.21037\/cdt-24-114","journal-title":"Cardiovasc Diagn Ther"},{"key":"13923_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","volume":"93","author":"C Campochiaro","year":"2021","unstructured":"Campochiaro C, Farina N, Tomelleri A et al (2021) Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med 93:87\u201394. https:\/\/doi.org\/10.1016\/j.ejim.2021.07.016","journal-title":"Eur J Intern Med"},{"issue":"3","key":"13923_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtho.2019.09.080","volume":"15","author":"H Wang","year":"2020","unstructured":"Wang H, Tian R, Gao P, Wang Q, Zhang L (2020) Tocilizumab for fulminant programmed death-1 inhibitor-associated myocarditis. J Thorac Oncol 15(3):31\u201331. https:\/\/doi.org\/10.1016\/j.jtho.2019.09.080","journal-title":"J Thorac Oncol"},{"issue":"1","key":"13923_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.annonc.2024.08.2340","volume":"36","author":"P-F Petit","year":"2025","unstructured":"Petit P-F, Daoudlarian D, Latifyan S et al (2025) Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study. Ann Oncol 36(1):43\u201353. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2340","journal-title":"Ann Oncol"},{"issue":"4","key":"13923_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S et al (2022) Defining cardiovascular toxicities of cancer therapies: an international cardio-oncology society (IC-OS) consensus statement. Eur Heart J 43(4):280\u2013299. https:\/\/doi.org\/10.1093\/eurheartj\/ehab674","journal-title":"Eur Heart J"},{"key":"13923_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","author":"AC Guidon","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK et al (2021) Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002890","journal-title":"J Immunother Cancer"},{"issue":"Suppl 1","key":"13923_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2020-eular.605","volume":"79","author":"J Aldrich","year":"2020","unstructured":"Aldrich J, Pundole X, Tummala S et al (2020) THU0336\u2005Immune checkpoint inhibitor-related myositis: a retrospective cohort study. Ann Rheum Dis 79(Suppl 1):399. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.605","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"13923_CR19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","volume":"31","author":"J Doms","year":"2020","unstructured":"Doms J, Prior JO, Peters S, Obeid M (2020) Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. Ann Oncol 31(9):1273\u20131275. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.005","journal-title":"Ann Oncol"},{"key":"13923_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1597259","volume":"16","author":"A S\u00e1nchez-Camacho","year":"2025","unstructured":"S\u00e1nchez-Camacho A, Torres-Zurita A, Gallego-L\u00f3pez L et al (2025) Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review. Front Immunol 16:1597259. https:\/\/doi.org\/10.3389\/fimmu.2025.1597259","journal-title":"Front Immunol"},{"issue":"6","key":"13923_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200484","volume":"12","author":"Y Segal","year":"2025","unstructured":"Segal Y, Mangioris G, Toledano M et al (2025) Outcomes in patients with immune checkpoint inhibitor\u2013related myopathy and prolonged follow-up. Neurol Neuroimmunol Neuroinflamm 12(6):e200484. https:\/\/doi.org\/10.1212\/NXI.0000000000200484","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13923_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101192","volume":"50","author":"L Plomp","year":"2025","unstructured":"Plomp L, Chassepot H, Psimaras D et al (2025) Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study. Lancet Reg Health Eur 50:101192. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101192","journal-title":"Lancet Reg Health Eur"},{"issue":"4","key":"13923_CR23","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s00415-023-12134-x","volume":"271","author":"A Vicino","year":"2024","unstructured":"Vicino A, Hottinger AF, Latifyan S et al (2024) Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series. J Neurol 271(4):1947\u20131958. https:\/\/doi.org\/10.1007\/s00415-023-12134-x","journal-title":"J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13923-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13923-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13923-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T17:09:54Z","timestamp":1781370594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13923-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["13923"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13923-w","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study protocol was approved by the University of Alberta Health Research Ethics Board (Pro00153935) in accordance with the Declaration of Helsinki. The retrospective study was considered minimal risk by the Research Ethics Board; therefore, the requirement for informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}],"article-number":"368"}}